Dope.de Develops New Optimized Antiestrogen Leads from Computer-aided de novo Design

TORONTO, Dec. 2 /CNW/ - Dope.de(R) Inc. of Guelph, Ontario, announces the achievement of an important milestone in its development of drug candidates for the treatment of breast cancer.

Biological testing has demonstrated that antiestrogens belonging to two chemical classes invented by Dope.de are active at pharmacological dosages. This result validates the ability of the company's proprietary computer-aided drug design technology to develop novel chemistry with specific biological activity rapidly and efficiently.

In competitive binding assays all the compounds tested showed significant activity compared to known compounds with high affinity for the estrogen receptor. This new information supports the positive results obtained earlier from MCF-7, gene transfection and cytotoxicity assays. Two novel chemical classes were discovered using Dope.de's proprietary technology process, Evolutionary Molecular Design™ (EMD.)

"Our new data demonstrates the ability of our proprietary process, Evolutionary Molecular Design™ (EMD) to generate novel chemical classes with predicted synthesizability and biological activity", says Ian Anderson, President & CEO. "This exciting success confirms the ability of the Dope.de team built by Dr. Jonathan Schmidt to provide optimized drug leads to the pharmaceutical industry."

Dope.de uses its proprietary EMD process for drug design and optimization. It constructs computer models that mimic the mechanism by which drugs interact in the body. These models are used to generate novel chemical structures. Selected structures are then evaluated for suitability for further development with pharmaceutical industry partners.